Epithalon

What is Epithalon?

Epithalon is a synthetic tetrapeptide consisting of four amino acids: alanine, glutamic acid, aspartic acid, and glycine (Ala-Glu-Asp-Gly). It was developed by Dr. Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, derived from the naturally occurring pineal gland polypeptide epithalamin.

Research into Epithalon spans more than four decades, making it one of the longest-studied longevity peptides, though the majority of published research originates from Russian institutions.

How Epithalon Works

The primary mechanism of interest involves telomerase activation:

• Telomerase upregulation: Epithalon appears to stimulate the expression of telomerase, the enzyme responsible for maintaining telomere length
• Telomere extension: Studies in cultured human cells have shown measurable increases in telomere length following Epithalon treatment
• Pineal modulation: The peptide may regulate pineal gland function, influencing melatonin secretion and circadian biology
• Antioxidant signaling: Some research indicates Epithalon reduces oxidative stress markers
• Gene expression regulation: Appears to influence expression of genes related to cellular aging

Research Summary

Telomere Research

A 2003 paper in Bulletin of Experimental Biology and Medicine demonstrated that Epithalon could induce telomerase activity and extend telomere length in human somatic cells — findings that generated significant interest in the longevity research community.

Animal Longevity Studies

Multiple studies in rodent models have reported life extension effects, with some studies showing increases in maximum lifespan by 15–25% compared to controls. Notably, several of these studies also observed reductions in spontaneous tumor incidence.

Human Studies

A limited number of small human studies, primarily in elderly populations, reported improvements in melatonin levels, immune function, and general health biomarkers. These studies were conducted in Russia and have not been independently replicated in Western clinical settings.

Circadian and Sleep Research

Research suggests Epithalon may normalize circadian rhythm disruptions common in aging, potentially through pineal gland modulation.

Safety Considerations

• Primary research base is in Russian literature; independent Western replication is limited
• No known human toxicity at research doses in published studies
• Long-term effects in healthy younger individuals are not established
• Typically administered via subcutaneous injection in research settings
• No standard dosing protocol established through controlled clinical trials

Medical Disclaimer: Epithalon is not approved by the FDA for human use. This information is for educational purposes only. Do not use peptides without consulting a licensed healthcare provider.

Legal & Regulatory Status

In the United States, Epithalon is not FDA-approved and is not on any bulk drug substance list permitting compounding. It is commercially available in some countries as a research compound. Its legal status for human use varies by jurisdiction.

Related Reading

• Epithalon: The Telomere Peptide — What Research Shows — Full review of Epithalon’s telomerase research, Russian studies, and evidence quality
• MOTS-c and KPV: Longevity Peptides in Research — Compare Epithalon with other mitochondrial and longevity-focused peptides
• Anti-Aging Peptides: What the Research Actually Shows — Broader context for anti-aging peptide claims
• Peptide Pipeline: Clinical Trials to Watch in 2026 — Epithalon observational study status and other ongoing research